Candela Wins FDA Clearance for Psoriasis Device

WAYLAND, Mass., Jan. 30 -- Candela Corp. has received clearance from the US Food and Drug Administration to market a laser for the treatment of psoriasis. The company said it is conducting on-going clinical trials and expects to market the device this coming summer.
Following acne, psoriasis is the second most common skin disorder in the United States, said Gerard E. Puorro, Candela's president and CEO. The market is underserved by current treatments. We are excited to be able to play a role in such a market.